Form 4: Labcorp Director Files Pre-Planned Stock Sale for July 2025

Labcorp Holdings Inc. Director Kerrii B. Anderson has filed a Form 4 disclosing a pre-planned sale of 500 shares of common stock at $265 per share, scheduled for July 1, 2025, under a Rule 10b5-1 plan.

Summary

• Kerrii B. Anderson, a Director of Labcorp Holdings Inc. (LH), reported a planned transaction involving the company's common stock.
• On July 1, 2025, Anderson is scheduled to dispose of 500 shares of common stock at a price of $265 per share.
• This transaction is being conducted pursuant to a Rule 10b5-1 plan, indicating it is a pre-scheduled sale for personal financial management.
• Following this planned transaction, Anderson will directly beneficially own 12,166 shares of common stock.
• Additionally, Anderson indirectly beneficially owns 144 shares through the Alexa M. Anderson Separate Trust and another 144 shares through the Cameron Taff Anderson Separate Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director selling shares can sometimes be perceived negatively, the explicit mention of a Rule 10b5-1 plan for a future transaction indicates a pre-planned event for personal financial management, rather than a reaction to adverse company-specific news, thus mitigating negative sentiment.

Positives

• The sale is explicitly stated to be conducted under a Rule 10b5-1 plan, which signifies a pre-arranged transaction not based on new, non-public information, thereby mitigating concerns typically associated with insider selling.

Negatives

• A director reducing their direct ownership stake, even through a planned sale, represents a decrease in their direct equity exposure to the company.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general implication of a director reducing their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future operational or financial outlook.

Industry Context

This specific insider transaction by a director is a routine disclosure for personal financial planning and does not inherently provide broader insights into industry trends or competitive dynamics within the healthcare diagnostics and laboratory services sector.

Related Party Transactions

• Indirect beneficial ownership of 144 shares each through the Alexa M. Anderson Separate Trust and the Cameron Taff Anderson Separate Trust are disclosed, indicating related party holdings.

Stakeholder Impact

• Shareholders: The planned sale of 500 shares by a director is a minor transaction relative to the company's overall outstanding shares and is unlikely to have a significant direct impact on shareholder value, especially given its pre-planned nature under a Rule 10b5-1 plan.
• Employees, Customers, Suppliers, Creditors: This type of filing has no direct impact on these stakeholders.

Next Steps

• The planned sale of 500 shares of common stock is scheduled to occur on July 1, 2025.

Key Dates

Keywords

Labcorp Holdings Inc., LH, SEC Form 4, Insider Transaction, Stock Sale, Director, Rule 10b5-1, Kerrii B. Anderson, Common Stock